Income Statement Aptose Biosciences Inc. OTC Markets

Stocks

APTO

CA03835T4081

Pharmaceuticals

Market Closed - OTC Markets 09:23:32 02/07/2026 pm IST			5-day change	1st Jan Change
1.690 ^USD	+0.90%		-.--%	+14.19%

02/07	Hanmi Pharmaceutical Closes Acquisition of Aptose Biosciences	MT
30/06	Hanmi Pharm. Co., Ltd. completed the acquisition of remaining 80.07% stake in Aptose Biosciences Inc..	CI

15d75cb54.SH2FKhOFPsnpJrNceeHqn7rs32kzImtoUmVg54CISZc.GTTmGkT_XZObS90KLruc8dC2vBkCEjsKASMhtcznAd8dTuFcVMN9n4Rh2A

Published financial data: APTOSE BIOSCIENCES INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Selling General & Admin Expenses, Total	1.95Cr	1.45Cr	1.56Cr	1.12Cr	1.34Cr
R&D Expenses	4.6Cr	2.81Cr	3.68Cr	1.51Cr	1.13Cr
Other Operating Expenses, Total	6.54Cr	4.26Cr	5.24Cr	2.63Cr	2.47Cr
Operating Income	-6.54Cr	-4.26Cr	-5.24Cr	-2.63Cr	-2.47Cr
Interest Expense, Total	-	-	-	-2L	-8L
Interest And Investment Income	94T	8L	11.51L	4L	1L
Net Interest Expenses	94T	8L	11.51L	2L	-7L
Currency Exchange Gains (Loss)	-1T	-9T	-2T	-9T	-7T
Other Non Operating Income (Expenses)	-	-	-	7L	-
EBT, Excl. Unusual Items	-6.54Cr	-4.18Cr	-5.12Cr	-2.54Cr	-2.55Cr
Other Unusual Items	-	-	-	-	-
EBT, Incl. Unusual Items	-6.54Cr	-4.18Cr	-5.12Cr	-2.54Cr	-2.55Cr
Earnings From Continuing Operations	-6.54Cr	-4.18Cr	-5.12Cr	-2.54Cr	-2.55Cr
Net Income to Company	-6.54Cr	-4.18Cr	-5.12Cr	-2.54Cr	-2.55Cr
Net Income - (IS)	-6.54Cr	-4.18Cr	-5.12Cr	-2.54Cr	-2.55Cr
Net Income to Common Incl Extra Items	-6.54Cr	-4.18Cr	-5.12Cr	-2.54Cr	-2.55Cr
Net Income to Common Excl. Extra Items	-6.54Cr	-4.18Cr	-5.12Cr	-2.54Cr	-2.55Cr
Per Share Items
Net EPS - Basic	-330.12	-203.98	-227.42	-36.38	-10.41
Basic EPS - Continuing Operations	-330.12	-203.98	-227.42	-36.38	-10.41
Basic Weighted Average Shares Outstanding	2L	2L	2L	7L	24.47L
Net EPS - Diluted	-330.12	-203.98	-227.42	-36.38	-10.41
Diluted EPS - Continuing Operations	-330.12	-203.98	-227.42	-36.38	-10.41
Diluted Weighted Average Shares Outstanding	2L	2L	2L	7L	24.47L
Normalized Basic EPS	-206.33	-127.49	-142.14	-22.74	-6.5
Normalized Diluted EPS	-206.33	-127.49	-142.14	-22.74	-6.5
Supplemental Items
EBITDA	-6.53Cr	-4.25Cr	-5.23Cr	-2.62Cr	-2.47Cr
EBITA	-6.54Cr	-4.26Cr	-5.24Cr	-2.63Cr	-2.47Cr
EBIT	-6.54Cr	-4.26Cr	-5.24Cr	-2.63Cr	-2.47Cr
EBITDAR	-6.48Cr	-4.2Cr	-5.18Cr	-2.58Cr	-2.43Cr
Normalized Net Income	-4.08Cr	-2.61Cr	-3.2Cr	-1.59Cr	-1.59Cr
Interest on Long-Term Debt	43T	-	-	2L	8L
Supplemental Operating Expense Items
General and Administrative Expenses	1.95Cr	1.45Cr	1.56Cr	1.12Cr	1.34Cr
Research And Development Expense From Footnotes	4.6Cr	2.81Cr	3.68Cr	1.51Cr	1.13Cr
Net Rental Expense, Total	5L	4L	5L	4L	4L
Imputed Operating Lease Interest Expense	-	-	-	1L	2L
Imputed Operating Lease Depreciation	-	-	-	3L	3L
Stock-Based Comp., R&D Exp. (Total)	37.9L	22.18L	13.73L	3L	2L
Stock-Based Comp., G&A Exp. (Total)	91.6L	29.89L	22.8L	7L	3L
Stock-Based Comp., Other (Total)	-	-	-	-	-
Total Stock-Based Compensation	1.3Cr	52.07L	36.53L	10.6L	5L

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Assets
Cash And Equivalents	3.91Cr	3.7Cr	92.52L	61.52L	9L
Short Term Investments	4Cr	99.89L	-	-	-
Total Cash And Short Term Investments	7.91Cr	4.7Cr	92.52L	61.52L	9L
Prepaid Expenses	24.76L	23.03L	20.42L	22.53L	22.09L
Restricted Cash	-	-	-	6L	31.61L
Other Current Assets, Total	1L	3L	6L	6L	1L
Total Current Assets	8.17Cr	4.95Cr	1.19Cr	95.3L	64.46L
Gross Property Plant And Equipment	27.51L	38.19L	37.03L	34.46L	34.18L
Accumulated Depreciation	-19.63L	-23.11L	-26.08L	-28.49L	-32.39L
Net Property Plant And Equipment	8L	15.08L	10.95L	6L	2L
Other Intangibles, Total	0	0	0	0	0
Other Long-Term Assets, Total	-	-	-	-	33.87L
Total Assets	8.25Cr	5.1Cr	1.3Cr	1.01Cr	1Cr
Liabilities
Accounts Payable, Total	16.99L	63.26L	60.46L	12.58L	29.11L
Accrued Expenses, Total	60.16L	56.57L	88.29L	27.73L	62.02L
Current Portion of Leases	5L	3L	4L	4L	2L
Total Current Liabilities	81.74L	1.23Cr	1.53Cr	44.59L	93.06L
Long-Term Debt	-	-	-	1Cr	2.7Cr
Long-Term Leases	1L	10.02L	6L	2L	-
Other Non Current Liabilities	-	-	-	-	9L
Total Liabilities	82.89L	1.33Cr	1.59Cr	1.47Cr	3.72Cr
Common Stock, Total	44Cr	44Cr	44Cr	46Cr	46Cr
Additional Paid In Capital	6.37Cr	6.89Cr	7.21Cr	8.33Cr	8.38Cr
Retained Earnings	-42Cr	-46Cr	-52Cr	-54Cr	-57Cr
Comprehensive Income and Other	-43.16L	-43.18L	-43.16L	-43.16L	-43.16L
Total Common Equity	7.42Cr	3.77Cr	-29.01L	-45.43L	-2.72Cr
Total Equity	7.42Cr	3.77Cr	-29.01L	-45.43L	-2.72Cr
Total Liabilities And Equity	8.25Cr	5.1Cr	1.3Cr	1.01Cr	1Cr
Supplemental Items
ECS Total Shares Outstanding on Filing Date	2L	2L	5L	25.52L	25.52L
ECS Total Common Shares Outstanding	2L	2L	3L	20.06L	25.52L
Book Value / Share	362.26	183.87	-10.96	-2.26	-10.64
Tangible Book Value	7.42Cr	3.77Cr	-29.01L	-45.43L	-2.72Cr
Tangible Book Value Per Share	362.26	183.87	-10.96	-2.26	-10.64
Total Debt	6L	13.03L	10.15L	1.06Cr	2.72Cr
Net Debt	-7.86Cr	-4.57Cr	-82.37L	44.87L	2.63Cr
Debt Equivalent Oper. Leases	41.2L	35.44L	37.68L	35.04L	34.32L
Account Code - Inventory Valuation	-	-	-	3	3
Machinery, Total	7L	5L	4L	2L	1L
Full Time Employees	41	35	35	13	14
Part Time Employees	1	1	1	-	-

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Net Income	-6.54Cr	-4.18Cr	-5.12Cr	-2.54Cr	-2.55Cr
Depreciation & Amortization - CF	6L	5L	5L	4L	22T
Depreciation & Amortization, Total	6L	5L	5L	4L	22T
(Gain) Loss From Sale Of Asset	-	16T	-	76T	-
Stock-Based Compensation (CF)	1.29Cr	52.07L	36.53L	10.6L	5L
Other Operating Activities, Total	75.18L	-21T	93T	-6L	12.73L
Change In Accounts Payable	-5L	46.27L	-3L	-47.88L	16.53L
Change in Other Net Operating Assets	14.33L	-9L	26.85L	-66.95L	53T
Cash from Operations	-4.33Cr	-3.23Cr	-4.46Cr	-3.6Cr	-2.2Cr
Capital Expenditure	-2L	-24T	-29T	-5T	-
Sale of Property, Plant, and Equipment	-	-	-	23T	-
Investment in Marketable and Equity Securities, Total	-3.5Cr	3.01Cr	99.89L	-	-
Other Investing Activities, Total	-	-	-	-	-
Cash from Investing	-3.52Cr	3.01Cr	99.6L	18T	-
Long-Term Debt Issued, Total	-	-	-	1Cr	1.86Cr
Total Debt Issued	-	-	-	1Cr	1.86Cr
Long-Term Debt Repaid, Total	-	-	-	-	-1L
Total Debt Repaid	-	-	-	-	-1L
Issuance of Common Stock	2L	1L	69.1L	2.34Cr	8L
Other Financing Activities, Total	-	-	-	-21T	-
Cash from Financing	2L	1L	69.1L	3.34Cr	1.94Cr
Foreign Exchange Rate Adjustments	7T	-4T	2T	-	-
Net Change in Cash	-7.83Cr	-21.44L	-2.77Cr	-25.45L	-26.11L
Supplemental Items
Levered Free Cash Flow	-2.6Cr	-1.66Cr	-2.58Cr	-2.67Cr	-1.25Cr
Unlevered Free Cash Flow	-2.6Cr	-1.66Cr	-2.58Cr	-2.65Cr	-1.2Cr
Change In Net Working Capital	-15.16L	-43.17L	-28.1L	1.16Cr	-29.49L
Net Debt Issued / Repaid	-	-	-	1Cr	1.86Cr

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Profitability
Return on Assets	-39.18	-39.87	-102.23	-141.98	-153.45
Return on Total Capital	-42	-46.77	-176.13	-779.6	-504.8
Return On Equity %	-67.67	-74.7	-293.96	683.23	160.63
Return on Common Equity	-67.67	-74.7	-293.96	683.23	160.63
Short Term Liquidity
Current Ratio	10	4.03	0.78	2.14	0.69
Quick Ratio	9.68	3.82	0.61	1.38	0.1
Operating Cash Flow to Current Liabilities	-5.3	-2.63	-2.92	-8.07	-2.36
Long Term Solvency
Total Debt/Equity	0.77	3.45	-34.99	-234.18	-100.16
Total Debt / Total Capital	0.77	3.34	-53.82	174.52	61.84T
LT Debt/Equity	0.15	2.65	-21.41	-224.76	-99.45
Long-Term Debt / Total Capital	0.15	2.57	-32.93	167.5	61.4T
Total Liabilities / Total Assets	10.04	26.04	122.33	144.86	371.34
EBIT / Interest Expense	-	-	-	-126.85	-29.33
EBITDA / Interest Expense	-	-	-	-124.57	-28.79
(EBITDA - Capex) / Interest Expense	-	-	-	-124.6	-28.79
Total Debt / EBITDA	-0.01	-0.03	-0.02	-0.41	-1.12
Net Debt / EBITDA	1.21	1.09	0.16	-0.17	-1.08
Total Debt / (EBITDA - Capex)	-0.01	-0.03	-0.02	-0.41	-1.12
Net Debt / (EBITDA - Capex)	1.21	1.09	0.16	-0.17	-1.08
Growth Over Prior Year
EBITDA, 1 Yr. Growth %	17.41	-34.94	23.04	-49.83	-5.81
EBITA, 1 Yr. Growth %	17.36	-34.91	22.9	-49.85	-5.84
EBIT, 1 Yr. Growth %	17.36	-34.91	22.9	-49.85	-5.84
Earnings From Cont. Operations, 1 Yr. Growth %	18.31	-36.01	22.44	-50.34	0.15
Net Income, 1 Yr. Growth %	18.31	-36.01	22.44	-50.34	0.15
Normalized Net Income, 1 Yr. Growth %	18.31	-36.01	22.44	-50.34	0.15
Diluted EPS Before Extra, 1 Yr. Growth %	8.69	-38.21	11.49	-84	-71.4
Net Property, Plant and Equip., 1 Yr. Growth %	-30.76	91.37	-27.39	-45.48	-70.02
Total Assets, 1 Yr. Growth %	-34.64	-38.17	-74.54	-22.03	-1.14
Tangible Book Value, 1 Yr. Growth %	-37.55	-49.16	-107.69	56.6	498
Common Equity, 1 Yr. Growth %	-37.57	-49.16	-107.69	56.6	498
Cash From Operations, 1 Yr. Growth %	27.77	-25.36	37.96	-19.32	-38.88
Capital Expenditures, 1 Yr. Growth %	168.35	-88.68	20.83	-82.76	-
Levered Free Cash Flow, 1 Yr. Growth %	98.02	-36.23	55.57	3.25	-53.65
Unlevered Free Cash Flow, 1 Yr. Growth %	98.02	-36.23	55.57	2.75	-55.38
Compound Annual Growth Rate Over Two Years
EBITDA, 2 Yr. CAGR %	56.37	-12.6	-10.53	-21.43	-31.26
EBITA, 2 Yr. CAGR %	56.1	-12.6	-10.56	-21.49	-31.28
EBIT, 2 Yr. CAGR %	56.1	-12.6	-10.56	-21.49	-31.28
Earnings From Cont. Operations, 2 Yr. CAGR %	57.71	-12.99	-11.48	-22.02	-29.48
Net Income, 2 Yr. CAGR %	57.71	-12.99	-11.48	-22.02	-29.48
Normalized Net Income, 2 Yr. CAGR %	57.71	-12.99	-11.48	-22.02	-29.48
Diluted EPS Before Extra, 2 Yr. CAGR %	18.34	-18.05	-17	-57.77	-78.61
Net Property, Plant and Equip., 2 Yr. CAGR %	-30.17	15.11	17.88	-37.08	-59.57
Total Assets, 2 Yr. CAGR %	-9.37	-36.43	-60.33	-55.45	-12.2
Tangible Book Value, 2 Yr. CAGR %	-11.05	-43.65	-80.23	-65.31	206.02
Common Equity, 2 Yr. CAGR %	-11.1	-43.66	-80.23	-65.31	206.02
Cash From Operations, 2 Yr. CAGR %	41.73	-2.34	1.47	5.5	-29.77
Capital Expenditures, 2 Yr. CAGR %	44.17	-44.88	-63.01	-54.36	-
Levered Free Cash Flow, 2 Yr. CAGR %	46.25	12.37	-0.4	26.74	-30.34
Unlevered Free Cash Flow, 2 Yr. CAGR %	46.25	12.37	-0.4	26.43	-31.82
Compound Annual Growth Rate Over Three Years
EBITDA, 3 Yr. CAGR %	31.04	16.74	-2.05	-26.22	-16.54
EBITA, 3 Yr. CAGR %	31.01	16.62	-2.08	-26.25	-16.59
EBIT, 3 Yr. CAGR %	31.01	16.62	-2.08	-26.25	-16.59
Earnings From Cont. Operations, 3 Yr. CAGR %	31.31	16.76	-2.49	-26.99	-15.24
Net Income, 3 Yr. CAGR %	31.31	16.76	-2.49	-26.99	-15.24
Normalized Net Income, 3 Yr. CAGR %	31.31	16.76	-2.49	-26.99	-15.24
Diluted EPS Before Extra, 3 Yr. CAGR %	-5.33	-4.71	-9.2	-52.06	-62.91
Net Property, Plant and Equip., 3 Yr. CAGR %	48.22	-2.28	-1.28	-8.84	-50.85
Total Assets, 3 Yr. CAGR %	69.76	-20.22	-53.14	-50.31	-41.89
Tangible Book Value, 3 Yr. CAGR %	74.63	-26.18	-70.99	-60.59	-10.38
Common Equity, 3 Yr. CAGR %	74.04	-26.21	-71	-60.59	-10.38
Cash From Operations, 3 Yr. CAGR %	23.11	14.45	9.58	-5.99	-12.05
Capital Expenditures, 3 Yr. CAGR %	-13.63	-38.26	-28.4	-71.32	-
Levered Free Cash Flow, 3 Yr. CAGR %	24.51	10.9	25.24	0.8	-8.94
Unlevered Free Cash Flow, 3 Yr. CAGR %	24.51	10.9	25.24	0.64	-10.24
Compound Annual Growth Rate Over Five Years
EBITDA, 5 Yr. CAGR %	35.76	29.33	12.49	-0.36	-14.98
EBITA, 5 Yr. CAGR %	35.6	29.22	12.46	-0.45	-15.01
EBIT, 5 Yr. CAGR %	35.6	29.22	12.46	-0.45	-15.01
Earnings From Cont. Operations, 5 Yr. CAGR %	35.63	29.14	12.15	-0.65	-14.35
Net Income, 5 Yr. CAGR %	35.63	29.14	12.15	-0.65	-14.35
Normalized Net Income, 5 Yr. CAGR %	35.63	29.14	12.15	-0.65	-14.35
Diluted EPS Before Extra, 5 Yr. CAGR %	-8.07	-2.78	-10.18	-31.18	-49.07
Net Property, Plant and Equip., 5 Yr. CAGR %	33.19	60.63	35.24	-18.06	-30.92
Total Assets, 5 Yr. CAGR %	57.02	33.65	-5.09	-36.8	-39.76
Tangible Book Value, 5 Yr. CAGR %	59.01	29.91	-26.94	-45.42	-25.56
Common Equity, 5 Yr. CAGR %	58.9	29.9	-27.09	-45.44	-25.57
Cash From Operations, 5 Yr. CAGR %	28.44	25.89	13.95	10.79	-8.29
Capital Expenditures, 5 Yr. CAGR %	134.34	13.05	-38.48	-45.29	-
Levered Free Cash Flow, 5 Yr. CAGR %	29.28	22.74	13.88	16.98	-0.95
Unlevered Free Cash Flow, 5 Yr. CAGR %	29.28	22.74	13.88	16.87	-1.8